InvestWiser

Genovis AB (publ.)

GENONasdaq StockholmHealthcareMarket value 1.5 bn SEK
22.50SEK 0.0%
last day · Price as of 18 November 2026

The answer first

Does Genovis beat the market?

No, Genovis has not beaten the market over the last year.

Genovis+12.5%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 52% of Nordic stocks

    • Quality77
    • Value9
    • Trend74

    No. 57 of 195 in healthcare

  • Expectations in the price

    High expectations

    For the share to return about 9% a year from today's price, the cash Genovis keeps must grow about 10% a year for 10 years.

Max for seven days

Follow Genovis with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Genovis

From today, at a price of 22.50 SEK. Write why you follow Genovis, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Genovis

Your first answer is free, no account needed.

Do you own Genovis, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Genovis and a few more. Free, no card.

Past year against the exchange and Super Stock
Genovis+12.5%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Genovis has risen 12.5% over the past year, including dividends.
  • Overall, Genovis ranks better than 52% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 77.0%. The price is 77.6% below its peak now.

What do analysts think of Genovis?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

52

Quality, value and trend together. Better than 52% of Nordic stocks.

No. 57 of 195 in healthcare

Quality77
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 64 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.49
  • Asset turnoverSales divided by everything the company owns0.34
  • Return on equityProfit divided by equity+5.3%
  • Cash conversionOperating cash flow divided by profit3.30

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value9
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 142 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity4.8
  • P/SPrice divided by sales10.1
  • P/EPrice divided by earnings89.9
  • P/CFPrice divided by operating cash flow27.2

The ranking is built on P/E, P/B and P/S.

Trend74
The share price · Technical: the price trend

High Tailwind in the share price: it has risen more than most over the last year.

No. 50 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months+11.9%
  • 6 months+9.5%
  • 9 months+31.9%
  • 12 months+12.5%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+11.1%
3 years, per year
−21.9%
5 years, per year
−22.7%
10 years, per year
+23.6%
Largest fall, 3 years
−77.0%
From a peak to the bottom
From the peak now
−77.6%
How far the price is from the peak
Volatility, 1 year
41.6%
How much the price swings over a year
Beta, 1 year
0.86
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Genovis

6 funds we follow own Genovis. The share is how much of the fund the stock makes up.

  • Norway1
  • Sweden5

From the funds' latest known holdings.

About Genovis

Genovis AB (publ.) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 36 employees.

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues.

See the full analysis of Genovis.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market